Eli Lilly to acquire Morphic in $3.2bn deal to expand integrin therapy development
In a major strategic move, Eli Lilly and Company (NYSE: LLY) has announced a definitive agreement to acquire Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical ... Read More